Skip to main content
Top
Published in: International Journal of Hematology 6/2013

01-06-2013 | Original Article

Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis

Authors: Daisuke Suzuki, Ryoji Kobayashi, Hirozumi Sano, Kenji Kishimoto, Kazue Yasuda, Masanori Nakanishi, Tetsuro Nagashima, Kunihiko Kobayashi

Published in: International Journal of Hematology | Issue 6/2013

Login to get access

Abstract

Langerhans cell histiocytosis (LCH) is sometimes resistant to conventional chemotherapies, and treatment with 2-chlorodeoxyadenosine (2-CdA) is gaining importance as a salvage treatment for refractory or recurrent LCH. Secondary malignancies such as acute myelogenous leukemia and myelodysplastic syndrome (MDS) due to 2-CdA have recently been reported. However, there have been no reports to date of cases of 2-CdA-related secondary MDS in which spontaneous remission was achieved. Here, we report the case of a 1-year-old boy with an occipital tumor who was diagnosed with LCH by biopsy and underwent chemotherapy. However, the disease relapsed and became refractory to chemotherapy. He received 2-CdA treatment, which was effective. However 6 months after the start of treatment, he developed MDS with chromosomal abnormality of 7q−. After 1-year observation without any intervention, his hematological findings had returned to normal, and the chromosomal abnormality had also disappeared. To our knowledge, this is the first report of 2-CdA-related MDS with spontaneous hematological remission.
Literature
1.
go back to reference Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–92.PubMedCrossRef Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–92.PubMedCrossRef
2.
go back to reference Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009;31:53–6.PubMedCrossRef Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009;31:53–6.PubMedCrossRef
3.
go back to reference Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999;33:476–81.PubMedCrossRef Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999;33:476–81.PubMedCrossRef
4.
go back to reference Jager G, Hofler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chlorodeoxyadenosine (2-CdA) treatement of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89:e1–3. Jager G, Hofler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chlorodeoxyadenosine (2-CdA) treatement of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89:e1–3.
5.
go back to reference Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol. 1999;105:268–70. Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol. 1999;105:268–70.
6.
go back to reference Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia. 1997;11:170.PubMedCrossRef Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia. 1997;11:170.PubMedCrossRef
7.
go back to reference Laurence FM, Zulian GB, Cabrol C, Betticher DC. Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy. Cancer Genet Cytogenet. 1997;99:85–9.CrossRef Laurence FM, Zulian GB, Cabrol C, Betticher DC. Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiation therapy. Cancer Genet Cytogenet. 1997;99:85–9.CrossRef
8.
go back to reference Delannoy A, Van den Neste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenstrom’s Macroglobulinaemia. Br J Haematol. 1999;104:933–4.PubMedCrossRef Delannoy A, Van den Neste E, Michaux JL, Bosly A, Ferrant A. Cladribine for Waldenstrom’s Macroglobulinaemia. Br J Haematol. 1999;104:933–4.PubMedCrossRef
9.
go back to reference Kong LR, Huang CF, Hakimian D, Variakojis D, Klein L, Kuzel TM, Gordon LI, Zanzig C, Wollins E, Tallman MS. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin lymphoma. Cancer. 1998;82:957–64.PubMedCrossRef Kong LR, Huang CF, Hakimian D, Variakojis D, Klein L, Kuzel TM, Gordon LI, Zanzig C, Wollins E, Tallman MS. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin lymphoma. Cancer. 1998;82:957–64.PubMedCrossRef
10.
go back to reference Parker TM, Klaassen RJ, Johnston DL. Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genet Cytogenet. 2008;182:122–5.PubMedCrossRef Parker TM, Klaassen RJ, Johnston DL. Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genet Cytogenet. 2008;182:122–5.PubMedCrossRef
11.
go back to reference Scheurlen W, Borkhardt A, Ritterbach J, Huppertz HI. Spontaneous hematological remission in a boy with myelodysplastic syndrome and monosomy 7. Leukemia. 1994;8:1435–8.PubMed Scheurlen W, Borkhardt A, Ritterbach J, Huppertz HI. Spontaneous hematological remission in a boy with myelodysplastic syndrome and monosomy 7. Leukemia. 1994;8:1435–8.PubMed
12.
go back to reference Leung EW, Woodman RC, Roland B, Abdelhaleem M, Freedman MH, Dror Y. Transient myelodysplastic syndrome associated with isochromosome 7q abnormality. Pediatr Hematol Oncol. 2003;20:539–45.PubMedCrossRef Leung EW, Woodman RC, Roland B, Abdelhaleem M, Freedman MH, Dror Y. Transient myelodysplastic syndrome associated with isochromosome 7q abnormality. Pediatr Hematol Oncol. 2003;20:539–45.PubMedCrossRef
13.
go back to reference Renneboog B, Hansen V, Heimann P, De Mulder A, Jannsen F, Ferster A. Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol. 1996;92:696–8.PubMedCrossRef Renneboog B, Hansen V, Heimann P, De Mulder A, Jannsen F, Ferster A. Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Br J Haematol. 1996;92:696–8.PubMedCrossRef
14.
go back to reference Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Eng J Med. 2004;351:1034–5.CrossRef Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Eng J Med. 2004;351:1034–5.CrossRef
15.
go back to reference Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans’-cell histiocytosis with etanercept. N Eng J Med. 2001;345:1577–8.CrossRef Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans’-cell histiocytosis with etanercept. N Eng J Med. 2001;345:1577–8.CrossRef
16.
go back to reference Weitzman S, Braier J, Egeler RM, Grois N, Ladisch S, Potschger U, Webb D, Whitlock J, Arceri RJ. 2′-Chlorodeoxyadenosine (2-CdA) as salvage for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009;53(7):1271–6.PubMedCrossRef Weitzman S, Braier J, Egeler RM, Grois N, Ladisch S, Potschger U, Webb D, Whitlock J, Arceri RJ. 2′-Chlorodeoxyadenosine (2-CdA) as salvage for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009;53(7):1271–6.PubMedCrossRef
17.
go back to reference Imamura T, Sato T, Shiota Y, Kanegane H, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Kamizono J, Morimoto A. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol. 2010;91:646–51.PubMedCrossRef Imamura T, Sato T, Shiota Y, Kanegane H, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Kamizono J, Morimoto A. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol. 2010;91:646–51.PubMedCrossRef
18.
go back to reference Yamada K, Yasui M, Sawada A, Inoue M, Nakayama M, Kawa K. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer. 2012;58:300–2.PubMedCrossRef Yamada K, Yasui M, Sawada A, Inoue M, Nakayama M, Kawa K. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer. 2012;58:300–2.PubMedCrossRef
19.
go back to reference Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin N Am. 1998;12:369–78.CrossRef Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin N Am. 1998;12:369–78.CrossRef
20.
go back to reference Petti MC, Latagliata R, Breccia M, Alimena G, Spadea A, D’Andrea M, Mancini M, Spiriti MAA, Mandelli F. Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. Haematologica. 2001;86:1277–80.PubMed Petti MC, Latagliata R, Breccia M, Alimena G, Spadea A, D’Andrea M, Mancini M, Spiriti MAA, Mandelli F. Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. Haematologica. 2001;86:1277–80.PubMed
Metadata
Title
Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis
Authors
Daisuke Suzuki
Ryoji Kobayashi
Hirozumi Sano
Kenji Kishimoto
Kazue Yasuda
Masanori Nakanishi
Tetsuro Nagashima
Kunihiko Kobayashi
Publication date
01-06-2013
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1343-7

Other articles of this Issue 6/2013

International Journal of Hematology 6/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine